Chromatin

GOAL	FOCUS	CELL NUMBER	RIGHT SERVICE FOR YOU
Global Accessibility	Open Chromatin		ATAC-seq
Target Specific	TF/Protein binding sites		ChIP-seq
Target Specific	Histone Modifications (Active/Inactive Chromatin)	High	ChIP-seq
Target Specific	Histone Modifications (Active/Inactive Chromatin)	Low	CUT&Tag

CHROMATIN

RNA

GOAL	FOCUS	RIGHT SERVICE FOR YOU
Whole Transcriptome	Ribosomal depleted RNA	Total RNA-seq
Coding RNAs	Poly-A RNA	mRNA-seq
Small non-Coding Circulating RNA	Short/cfRNA	Small RNA-seq

RNA

DNA Methylation

GOAL	SAMPLE TYPE	FOCUS	RIGHT SERVICE FOR YOU	COVERAGE
Biomarker Discovery	gDNA FFPE	Cancer	EPIC Array	~930k CpGs
Biomarker Discovery	gDNA FFPE	Epidemiology	Methylation Screening Array	~270k CpGs
Biomarker Discovery	gDNA FFPE	Mouse	Mouse Methylation Array	~285k CpGs
Biomarker Discovery	gDNA	CpG-rich regions	RRBS	~2–7M CpGs
Biomarker Discovery	gDNA cfDNA	Biologically relevant regions	Human Methylome	~9M CpGs
Biomarker Discovery	gDNA cfDNA	Whole genome	EM-seq	>50M CpGs
Biomarker Discovery	gDNA FFPE cfDNA	Whole genome	WGBS	>50M CpGs
Biomarker Validation	gDNA cfDNA	Selected CpGs	Targeted Methyl-seq	Variable/custom

DNA METHYLATION

About Us

Hologic Diagenode stands at the forefront of the epigenomics field, boasting over two decades of expertise. Our advanced services facilitate biomarker discovery and validation by integrating cutting-edge technologies with sophisticated bioinformatics. By delving into the new dimension of epigenomics, we unlock profound insights that transcend genomics, supporting early detection, patient screening, minimal residual disease (MRD) monitoring, and more. We collaborate closely with you to deliver a tailored, end-to-end service, leveraging premier technology to accelerate timelines from R&D to translational research and clinical trials.

Our Service Laboratory Facilities:

USA: San Diego, CA
CLIA environment*

Europe: Liège, Belgium

***Note:** Epigenomic testing services are research use only and do not necessarily comply with all CLIA requirements.*

EU // Liège Science Park / Rue Bois Saint-Jean 3, 4102 Seraing / BE / Phone : +32 4 364 20 50 / Fax : +32 4 364 20 51
US // 400 Morris Avenue / Suite 101 Denville / NJ 07834 / USA / Phone : +1 862 209 4680 / Fax : +1 862 209 4681
www.diagenode.com

DNA Methylation in Liquid Biopsies: Overcoming Early Detection Challenges in Cancer

We leveraged our 20 years of epigenomic expertise to help Universal Diagnostics (UDx) develop a customized early-detection workflow for colorectal cancer (CRC), integrating liquid biopsies with DNA methylation technologies for biomarker discovery and validation.

Capturing Biomarkers in Real-Time with Liquid Biopsy

Using cell-free DNA (cfDNA) isolated from plasma, biomarkers were monitored in real-time in the risk population.

DNA Methylation for Cancer Classification

Genome-wide methylation profiles from healthy and cancer patients were created to identify potential biomarkers.

Biomarker Validation

Once a pool of potential biomarkers was available, the best performers were identified.

Learn more

Our Multi-Omics Approach



BIOINFORMATICS
Statistical Analysis
Integrative Multi-omics
AI and Machine Learning

Our Services by the Numbers

40,000+
samples
including liquid biopsies

250+
projects
Biotech & Pharma

600+
projects
Academia/Government/
Nonprofit Organization (NPO)

AI and Epigenomics: Powering Biomarker Signature Identification

DNA methylation signatures are highly sensitive and specific, making them ideal for early detection, surveillance screening, and monitoring of minimal residual disease (MRD) for cancer and beyond.

DNA Methylation Profiling

Tissue-specific and cancer-specific DNA methylation profiles can be found in previously published and publicly available databases or via genome-wide de novo analysis, such as our WGBS/EM-seq, Human Methylome and EPIC array.

AI and Machine Learning (ML)

Biomarker signatures can be identified bioinformatically using AI and ML analysis approaches.

Biomarker Validation

Biomarkers could then be validated on an independent cohort, publicly available or via new data generated from our custom Targeted Methyl-seq.

Learn more

Why Choose Us?

Profound Biological Insights

Harnessing the power of **epigenomics** combined with advanced **AI** on **clinical samples**, we propel your biomarker discovery to a new dimension.

Accuracy and Reliability

Leveraging our **expertise** in **cutting-edge techniques**, methodologies and platforms, we identify biomarkers with unprecedent precision.

Faster Time to Market

Partner with us to experience a comprehensive journey with **streamlined timelines**, from R&D to clinical trials, accelerating your path to market.

HOLOGIC®
Diagenode

Accelerating Biomarker Discovery with Epigenomics